Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)

USA |NYSE MKT |USD

Price
$ 7.99
Change
0.25%
Today's Range
$7.79 - $8.24
52-Week Range
$5.70 - $11.90
Market Cap
$175.97M
Volume
133.52K

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

(NYSEAMERICAN:ATNM) Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.
Show more

ATNM Stock Price

Statistics Highlights (NYSEAMERICAN:ATNM)

Shares Outstanding 22.02M Beta 0.57
Public Float 21.69M P/E Ratio -
% Short of Float - Dividend (Yield) -
Held by Insiders 1.41% Ex-Dividend Date
Held by Institutions 13.84% IPO Date Dec 27, 2012

ATNM Financial Summary

|
Dec 20 Dec 19 Dec 18
Revenue $0.00 $0.00 $0.00
EBITDA $-21.77M $-21.65M $-23.78M
Net Income $-22.21M $-21.90M $-23.65M
Total Assets $66.40M $11.67M $14.89M
Total Cash $63.56M $9.25M $13.67M
Total Debt $342.00K $1.43M $262.59K
Sep 21 Jun 21 Mar 21
Revenue $233.00K $266.00K $622.00K
EBITDA $-6.21M $-4.95M $-5.25M
Net Income $-6.42M $-5.02M $-5.32M
Total Assets $84.48M $84.45M $75.10M
Total Cash $82.03M $81.91M $72.25M
Total Debt $333.00K $529.00K $634.00K

ATNM Stock Price History

Actinium Pharmaceuticals Annual Stock Price History

Year Open Close Change
2021 $6.03 $7.99 32.50%
2021 $8.30 $6.03 -27.35%
2020 $0.23 $8.30 3574.19%

Actinium Pharmaceuticals Daily Stock Price History

Date Open High Low Close Change Volume
Jun 9, 2022 $5.40 $5.40 $5.14 $5.20 -0.19% 87.13K
Jun 22, 2022 $5.20 $5.37 $5.12 $5.21 8.77% 176.82K
Jun 13, 2022 $4.95 $5.01 $4.72 $4.79 -7.88% 216.30K

(NYSEAMERICAN:ATNM) Stock Price FAQs

What is today's stock price of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)?

  • The current stock price of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) is $7.99.
  • Today ATNM stock price opened at $8.19 after previous close of $7.97.
  • During the day, Actinium Pharmaceuticals stock quote has varied from a low of $7.79 to a high of $8.24.

What is Actinium Pharmaceuticals's 52-week change?

  • ATNM 52-week high stock quote is $11.90, which is 48.90% above the current share price.
  • The Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) 52-week low stock price is $5.70, which is 28.70% below the current share price.
  • Actinium Pharmaceuticals share price volatility (52-week beta) is 0.57.

Is Actinium Pharmaceuticals a buy?

  • According to 4 analysts, the current consensus recommendation for Actinium Pharmaceuticals stock is "Strong Buy" at an average rating score of 4.50 (out of 5).
  • There are currently 2 "Strong Buy", 2 "Buy", 0 "Hold", 0 "Sell", and 0 "Strong Sell" analysts recommendations for the ATNM stock.
  • The 12 month average price target forecast for ATNM stock is $30.00, representing a 275.50% increase from the current ATNM stock price of $7.99.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) FAQ

How Much is Actinium pharmaceuticals Worth?

Actinium pharmaceuticals's worth today based on market capitalisation is $175.97M

How much dividend does Actinium pharmaceuticals Pay?

The current annualized dividend payout for ATNM stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Actinium pharmaceuticals's "Dividend" Section

What is Actinium pharmaceuticals’s Price to Earning (PE) ratio?

ATNM stock also has a Price to Sales (P/S) ratio of 156.98, a Price to Book of 2.15 and Price/Earnings to Growth (PEG) of 0.00.

What is the Actinium pharmaceuticals's ticker?

Actinium pharmaceuticals trades on the NYSE American stock market in USA under the ticker symbol "ATNM". Actinium pharmaceuticals’s stock symbol can also be displayed as "NYSEAMERICAN:ATNM".

When did ATNM go public?

Actinium pharmaceuticals completed its initial public offering (IPO) on December 27 ,2012.

Who are the owners of Actinium pharmaceuticals?

Actinium pharmaceuticals (NYSEAMERICAN:ATNM) is owned by 13.84% institutional shareholders and by 1.41% insiders. The rest is owned by the public.
Explore More Details on Actinium pharmaceuticals's “Ownership” Section

Who are the key executives of Actinium pharmaceuticals (ATNM)?

Actinium pharmaceuticals's key executive team includes the following managers:

  • Mr. Sandesh C. Seth M.B.A., M.S., MBA, Chairman & CEO (1964)
  • Mr. Steven O'Loughlin BS, CFO & Corp. Sec. (1986)
  • Dr. Paul Diamond Esq., Ph.D., VP of Patent & Legal Counsel (NA)
  • Dr. David Gould, Sr. VP of Corp. Devel. & Corp. Affairs (NA)
  • Dr. Bernie Cunningham, Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management (NA)
  • Dr. Qing Liang, VP & Head of Radiation Sciences (NA)
  • Dr. Robert N. Daly M.S., Ph.D., VP & Head of Clinical Operations (NA)
  • Dr. Mamata Gokhale, VP & Global Head of Regulatory Affairs (NA)
  • Dr. Avinash Desai M.D., Chief Medical Officer (NA)
  • Dr. Arun Swaminathan Ph.D., Chief Bus. & Commercial Officer (NA)

What is Actinium pharmaceuticals’s Sector & Industry Classification?

Actinium pharmaceuticals (NYSEAMERICAN:ATNM) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Actinium pharmaceuticals?

Currently the number of employees working for Actinium pharmaceuticals is 32.

Where are Actinium pharmaceuticals's Headquarters?

Actinium pharmaceuticals (NYSEAMERICAN:ATNM) is headquartered in NY, United States.

What are Actinium pharmaceuticals's Address and Phone Number?

Actinium pharmaceuticals’s mailing address is 275 Madison Avenue, New York, NY, United States, 10016.
The company’s phone number is 646 677 3870.

What is the official website for Actinium pharmaceuticals?

Actinium pharmaceuticals’s official website is http://www.actiniumpharma.com